{
  "documents": [
    {
      "id": "cluster_2_doc1",
      "content": "Patient 47823-9K underwent targeted immunotherapy at Silver Pine Clinic in March 2022. The treatment was part of a research study on rare autoimmune responses. Records indicate the patient resides at 2254 Willow Lane and had previously exhausted conventional treatment options. Provider notes mention concerns about possible hyper-inflammatory reactions requiring close monitoring.",
      "metadata": {
        "format": "medical_record"
      }
    },
    {
      "id": "cluster_2_doc2",
      "content": "Silver Pine Clinic reported 14 adverse events in Q2 2022 related to experimental autoimmune therapies, with one requiring ICU transfer. This prompted network-wide protocol updates effective August 2022. Claims processors were instructed to flag cases with diagnosis codes 994.2 and 999.3 for additional clinical review before approval.",
      "metadata": {
        "format": "insurance_memo"
      }
    },
    {
      "id": "cluster_2_doc3",
      "content": "A patient survey from 2254 Willow Lane indicates satisfaction with care coordination but frustration with prior authorization delays for research-based treatments. Respondent noted 6-week wait times for specialty drug approvals despite urgent medical need.",
      "metadata": {
        "format": "patient_survey"
      }
    },
    {
      "id": "cluster_2_doc4",
      "content": "Policy update CM-8871 now requires pre-authorization genetic testing for all patients entering immunotherapy protocols. This applies specifically to Silver Pine Clinic and two other research facilities. Implementation began October 15 with a 30-day grace period.",
      "metadata": {
        "format": "policy_document"
      }
    },
    {
      "id": "cluster_2_doc5",
      "content": "Local news outlet River Times reported on March 5 about increased insurance denials for novel autoimmune treatments at Silver Pine Clinic. The article referenced patient advocates arguing these decisions counter recent research findings published in Clinical Immunology Reviews.",
      "metadata": {
        "format": "news_article"
      }
    }
  ],
  "metadata": {
    "category": "cluster",
    "cluster_id": "cluster_2",
    "cluster_risk": "MEDIUM",
    "content_summary": "Patient undergoing experimental immunotherapy at Silver Pine Clinic, associated policy changes, and systemic response to adverse events",
    "person": {
      "entities": [
        [
          "47823-9K",
          "PATIENT_ID"
        ],
        [
          "2254 Willow Lane",
          "ADDRESS"
        ],
        [
          "March 2022",
          "EVENT_DATE"
        ],
        [
          "targeted immunotherapy",
          "MEDICAL_CONDITION"
        ],
        [
          "autoimmune responses",
          "MEDICAL_CONDITION"
        ],
        [
          "hyper-inflammatory reactions",
          "MEDICAL_CONDITION"
        ],
        [
          "Silver Pine Clinic",
          "LOCATION"
        ],
        [
          "6-week",
          "UNIQUE_FACT"
        ]
      ]
    },
    "questions": [
      {
        "q": "What was the street address of the patient who underwent targeted immunotherapy at Silver Pine Clinic in March 2022?",
        "a": "2254 Willow Lane",
        "sources": [
          "cluster_2_doc1"
        ],
        "type": "specific"
      },
      {
        "q": "What policy reference number introduced genetic testing requirements for immunotherapy protocols?",
        "a": "CM-8871 implemented October 15 with grace period",
        "sources": [
          "cluster_2_doc4"
        ],
        "type": "general"
      },
      {
        "q": "Which two medical concerns were documented for patient 47823-9K during immunotherapy treatment?",
        "a": "Rare autoimmune responses and possible hyper-inflammatory reactions",
        "sources": [
          "cluster_2_doc1",
          "cluster_2_doc2"
        ],
        "type": "specific"
      },
      {
        "q": "What operational changes occurred at Silver Pine Clinic after Q2 2022 adverse events?",
        "a": "Protocol updates and mandatory clinical review for specific diagnosis codes",
        "sources": [
          "cluster_2_doc2",
          "cluster_2_doc5"
        ],
        "type": "general"
      }
    ]
  }
}